This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Oct 28;173(19):1842-3.

doi: 10.1001/jamainternmed.2013.8138.

Glucagon-like peptide 1-based drugs and pancreatic safety

Kimberly G Brodovicz¹, Samuel S Engel, Nancy A Thornberry

Affiliations

PMID: 24165844
DOI: 10.1001/jamainternmed.2013.8138

Comment

Glucagon-like peptide 1-based drugs and pancreatic safety

Kimberly G Brodovicz et al. JAMA Intern Med. 2013.

. 2013 Oct 28;173(19):1842-3.

doi: 10.1001/jamainternmed.2013.8138.

Authors

Kimberly G Brodovicz¹, Samuel S Engel, Nancy A Thornberry

Affiliation

¹ Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey.

PMID: 24165844
DOI: 10.1001/jamainternmed.2013.8138

No abstract available

PubMed Disclaimer

Comment in

Glucagon-like peptide 1-based drugs and pancreatic safety--reply.
Singh S. Singh S. JAMA Intern Med. 2013 Oct 28;173(19):1843-4. doi: 10.1001/jamainternmed.2013.8128. JAMA Intern Med. 2013. PMID: 24165846 No abstract available.

Comment on

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Singh S, et al. JAMA Intern Med. 2013 Apr 8;173(7):534-9. doi: 10.1001/jamainternmed.2013.2720. JAMA Intern Med. 2013. PMID: 23440284

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information